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Psychiatric disorders frequently co-
occur with HIV infection, as conditions 
preceding or consequent to infection. 
A high degree of adherence to highly 
active antiretroviral therapy (HAART) 
is required to prevent the development 
of resistant viral strains and to minimise 
the risk of medication failure. Psychiatric 
co-morbidities potentially compromise 
adherence to antiretroviral therapy (ART) 
and can complicate HIV diagnosis and 
treatment. Although close collaboration 
between physicians, psychiatrists and 
other members of the multidisciplinary 
team is the ideal, psychiatric support is 
not readily available in certain settings. 
This article is intended to guide the 
diagnosis and psychotropic treatment 
of common mental disorders in people 
living with HIV/AIDS (PLWHA). 
Many psychotropics are taken for ≥6 
months, and both psychotropics and 
antiretrovirals (ARVs) are metabolised 
by the cytochrome P450 enzyme 
system, necessitating consideration of 
pharmacokinetic interactions. There 
also needs to be awareness of the 
differences in medication responses and 
tolerability in this population. Here we 
summarise: prescribing psychotropics 
in HIV; neuropsychiatric side-effects of 
ARVs and other medications commonly 
prescribed in HIV; and the diagnosis 
and treatment of depression, anxiety, 
psychosis, agitation, sleep disturbance, 
pain, and mania. The psychotropic 
treatments recommended here were 
drawn primarily from those available in 
the public sector of South Africa (SA). 
Psychotropics 
in HIV: basic 
principles 
A few simple points should be kept in 
mind when considering the management 
of mental disorders in HIV-infected 
individuals. Firstly, patients with HIV 
infection are generally very sensitive 
to medication side-effects as they often 
metabolise drugs more slowly, have less 
lean body mass and have compromised 
blood-brain barrier functioning. 
Although most patients ultimately tolerate 
standard doses of most medications, 
it is advisable to start at low doses and 
escalate dosing slowly over time.1,2 
Furthermore, PLWHA often receive 
multiple medications (ARVs, antibiotics, 
tuberculosis (TB) medications, etc.). 
Consequently, healthcare providers 
need to avoid prescribing complex 
regimens (e.g. daily dose instead of twice 
daily, where possible), anticipate drug 
interactions, and consider possible mood, 
behavioural and cognitive effects of 
medications such as ARVs.
The fact that treating HIV infection 
and related conditions is essential for 
optimal psychiatric care is often under-
appreciated. Close collaboration between 
psychiatrists, physicians, nursing staff 
and all members of the multi-disciplinary 
healthcare team is crucial. It is important 
to make the distinction between primary 
and secondary psychiatric symptoms (e.g. 
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those caused by other medications, delirium, 
central nervous system (CNS) infections, etc.), 
as results of standard psychiatric treatment may 
be inadequate if these are not addressed.1 
ARV neuropsychiatric 
side-effects
The introduction of HAART has transformed 
HIV infection from a death sentence to a 
chronic treatable illness. Unfortunately, most 
ARVs have neuropsychiatric side-effects 
(Table 1),2 most commonly insomnia and 
headache, with efavirenz (EFV) being the 
agent most often implicated. These symptoms 
usually emerge shortly (within 3 months) after 
commencing ARVs and abate on withdrawal 
thereof. Although EFV is not absolutely 
contra-indicated in patients with a history 
of severe mental illness, patients should be 
informed of potential side-effects and closely 
monitored for any emergence or exacerbation 
of symptoms. Furthermore, where possible, 
alternative ARVs should be considered. The 
optimal HAART regimen for patients with 
CNS disease remains to be established. It is 
unclear whether ARV regimens with better 
CNS penetration are superior to others,3 but 
there is consensus that optimal peripheral viral 
suppression is necessary.4
Depression
Depressive disorder is common in HIV-
positive individuals, with a prevalence of 
11.1% for major depressive disorder and 
29.9% for mild depression in SA clinics.5 It 
has been suggested that depression is often 
under-diagnosed2 and insufficiently managed.6 
The following screening questions may prove 
helpful in identifying patients requiring 
further treatment or referral:
• ‘During the past month, have you often 
been bothered by feeling down, depressed 
or hopeless?’
• ‘During the past month, have you often 
been bothered by little interest or pleasure 
in doing things?’
• ‘Is this something with which you would 
like help?’
It is also important to ask patients about 
suicidal thoughts, self-esteem, feelings 
of guilt or worthlessness, and outlook. 
Although the Diagnostic and Statistical 
Manual of Mental Disorders (Fourth Edition) 
(DSM-IV) includes problems with sleep, 
energy and appetite as diagnostic criteria for 
depression, these may be HIV-related.
If the patient answers ‘yes’ to one or 
more of the above questions, it is  helpful 
to differentiate between mild-moderate 
and severe depression, to inform further 
management. In mild-moderate depression, 
patients usually experience transient or mild 
symptoms occasionally, have low levels of 
distress, and do not have suicidal thoughts or 
plans. Such symptoms can often be in relation 
to a recent diagnosis or the commencement of 
ARV treatment. These patients can be referred 
to a supportive adherence counsellor or can be 
considered for referral for psychotherapy where 
psychologists are available. In cases of severe 
depression, patients often have persistent, 
severe symptoms, high levels of distress and 





Didanosine (ddI) • Common: insomnia, mania
Lamivudine (3TC) • Rare: insomnia, mania, restlessness, agitation, delirium, depression, irritability
Stavudine (d4T) • Headache, insomnia, mania, abnormal dreams, anxiety, depression, 
somnolence, emotional lability 
Tenofovir (TDF) • Common: aesthenia, depression, insomnia, anorexia (possibly related to 
co-use of EFV)
Zidovudine (AZT) • Common: insomnia, anorexia, dizziness




Efavirenz (EFV) • Common: depression, dizziness, insomnia, somnolence, impaired 
concentration, vivid dreams, and anxiety
• Rare: agitation, paranoia, delusions, euphoria, confusion, amnesia, 
depersonalisation, hallucinations, suicidal ideation, convulsions, false-positive 
cannabinoid test
Protease inhibitors (PIs) Lopinavir/ritonavir (LPV/r) • Rare: parasthaesia, insomnia, reduced libido, anxiety, abnormal dreams
Ritonavir (RTV) • Common: aesthenia, circumoral and peripheral paresthaesia, altered taste
Atazanavir (ATV/r) • Common: dizziness, insomnia
• Rare: depression, confusion, amnesia, abnormal dreams, anxiety
Antibacterials Co-trimoxazole • Rare: insomnia, depression, anorexia, apathy
Isoniazid (INH) • Common: peripheral neuropathy 
• Rare: agitation, depression, hallucinations, paranoia, impaired memory
Other Metronidazole • Rare: CNS toxicity, agitation, depression, delirium, seizures
Amphotericin B • Common: headache 
• Rare: delirium, agitation, anorexia, lethargy, diplopia
Steroids • Euphoria, mania, depression, psychosis, confusion
CNS = central nervous system.
*Common: <10%; rare: <1%.





suicidality. These patients should be referred 
to psychiatric services and/or treatment with 
antidepressant medication should be initiated.
Antidepressants
Using more than one antidepressant should 
be avoided, as the risk of serotonin syndrome 
may be increased in HIV-positive patients.2 
The syndrome, which constitues a medical 
emergency, presents with pyrexia, sweating, 
diarrhoea, hyperreflexia, myoclonus, loss of 
consciousness and seizures.
In general, the duration of treatment 
with antidepressant medication depends on 
whether or not the patient has experienced 
previous depressive episodes. For a first 
episode, medication should generally be 
continued for 6 - 12 months to prevent relapse. 
Treatment should be continued for 2 - 3 years 
in the event of a patient’s second or third 
episode, and lifelong medication should be 
considered for >3 prior episodes.
St John’s wort, a herbal product with 
antidepressant effects, may reduce the plasma 
concentrations and clinical effects of EFV, 
nevirapine (NVP) and lopinavir/ritonavir 
(LPV/r). Patients must therefore be informed 
that its concurrent use with these ARVs is 
contra-indicated.7
First-line agents include the serotonin 
selective re-uptake inhibitors (SSRIs), 
fluoxetine (for patients on first-line ART 
regimens) or citalopram (for patients on 
second-line regimens or receiving protease 
inhibitors (PIs)). In most public sector 
facilities, treatment with citalopram needs to 
be initiated by a psychiatrist. The side-effects, 
drug interactions and potential advantages of 
these SSRIs are outlined in Table 2.
If the patient has a co-morbid sleep disorder 
or chronic pain, tricyclic antidepressants 
(TCAs), such as amitriptyline or imipramine, 
should be considered (Table 3). These can be 
prescribed as monotherapy: 100 - 150 mg/day, 
or 25 - 50 mg/day as augmentation.
In patients with co-morbid anxiety and/or 
patients who have not responded to SSRIs, the 
use of venlafaxine (Efexor) – a serotonin and 
noradrenaline re-uptake inhibitor (SNRI) – 
could be considered. The drug is not available 
at all centres and needs to be initiated by a 
psychiatrist (at a dose of 37.5 mg/day, increased 
to a maximum of 225 mg/day). Treatment 
with venlafaxine should never be stopped 
abruptly, as discontinuation symptoms can 
occur. Potential side-effects include nausea, 
insomnia, dry mouth, somnolence, sweating, 
headache, nervousness, constipation, sexual 
dysfunction and elevation of blood pressure at 
higher doses. The drug should be avoided in 
patients at risk of arrhythmia.2 
Anxiety
Anxiety is a normal human emotion and may 
be adaptive in many circumstances. However, 
when it is present for prolonged periods of time, 
is excessive in relation to the person’s current life 
stressors, or interferes with daily functioning, 
an anxiety disorder may be present. Anxiety 
symptoms often mimic common mental 
conditions and may occur as part of depression, 
or alone. It is important to exclude and treat 
physical causes that can resemble the physical 
symptoms of anxiety, such as thyroid disease, 
cardiac disease and seizures. The DSM-IV 
Table 2. Side-effects, drug interactions and advantages of concurrent SSRI use with ART
Agent Dose Side-effects Drug interactions8,9 Notes
Fluoxetine 20 - 60 
mg/day 
Nausea, dyspepsia, 
abdominal pain, anxiety 
(especially in first 10 
days), headache, tremor, 
sexual dysfunction, 
hyponatraemia, 
insomnia and agitation 
• LPV/r: may increase fluoxetine 
levels – increased risk of serotonin 
syndrome 
• Advantages: low cost, available at 
most centres
• Agitation can be a big problem 
in the first few days: adequate 
explanation and reassurance can 
reduce impact
• Safe in overdose
Citalopram 20 - 60 
mg/day
As for fluoxetine • Not a potent inhibitor of most 
cytochrome-P450 enzymes: few drug 
interactions
• Use with caution with NSAIDs/
warfarin
• Advantage over fluoxetine: starting 
dose can be halved (10 mg), and 
fewer drug interactions
• Safe in overdose
LPV/r = lopinavir/ritonavir; SSRI = serotonin selective re-uptake inhibitor; NSAIDs = non-steroidal anti-inflammatory drugs.
Table 3. Side-effects, drugs interactions and advantages of concurrent TCA  use with ART 
Agent Dose Side-effects Drug interactions8,9 Notes





• Dry mouth, blurred vision, 
constipation, urinary retention, 
sedation, arrhythmia
• Contra-indicated if myocardial 
infarct in preceding 6 
months, cardiac conduction 
abnormalities or prostatism
RTV: increases levels 
and thereby the 
antimuscarinic effects 
of amitriptyline (reduce 
the dose)
• Lethal in overdose: not suitable for 
patients at risk of suicide 
• Dry mouth can be a problem with oral 
candida
• Usual dose of 25 mg for insomnia 
or pain is often not sufficient as an 
antidepressant – may need >3 tablets
• Useful if sedation/analgesia is required
Imipramine 75 - 150 
mg/day
As for amitriptyline, but less 
sedating
TCA = tricyclic antidepressant; RTV = ritonavir.





distinguishes between the following anxiety 
disorders: 
• generalised anxiety disorder (GAD): 
excessive and pervasive worry and tension 
about a variety of events and activities in 
daily life, associated with somatic symptoms
• panic disorder: recurrent, unexpected 
sudden attacks of overwhelming anxiety
• phobias: excessive fears of specific objects 
(e.g. spiders) or situations (e.g. flying or 
social situations)
• post-traumatic stress disorder (PTSD): 
distressing dreams or flashbacks, nervousness, 
poor sleep and avoiding reminders following 
a life-threatening or traumatic event
• obsessive-compulsive disorder (OCD): 
repetitive, uncontrollable thoughts or images 
that are disturbing; or an inability to cease 
performing rituals or repetitive actions.
If symptoms of the above disorders are 
present for ≥1 month, where possible, we 
advise considering pharmacotherapy and 
referral to a psychologist. SSRIs are considered 
first-line treatment. Importantly, people with 
anxiety disorders may be particularly prone 
to adverse effects and tolerate high initial 
doses poorly.10 Patients with anxiety generally 
require higher doses of SSRIs than those with 
depression; however, medication should be 
titrated up cautiously to moderate side-effects. 
Antidepressants for anxiety may need to be 
taken for 12 months after the remission of 
symptoms, depending on the diagnosis.
Table 4. Benzodiazepine use with ART
Benzodiazepines (short-term prescribing only)
Long-acting (half-life >20 hours) • Diazepam (Pax, Valium): 2 - 30 mg (oral or IV; never IM) up to 3 times daily
• Clonazepam (Rivotril): 0.5 - 2 mg twice daily
Intermediate-acting (12 - 24 hours) • Lorazepam (Ativan, Tranqipam): 1 - 12 mg (oral, IM or sublingual) up to 3 
times daily
• Alprazolam (Alzam, Xanor): 0.25 - 4 mg (see interactions below) twice daily
Short-acting (6 - 12 hours) • Oxazepam 10 - 30 mg twice daily
Ultra-short-acting (<6 hours) • Midazolam (Dormicum): 7.5 - 15 mg (see interactions below) usually stat dose, 
but may be used up to 3 times daily
Benzodiazepine interactions with ARVs8,9
Diazepam • Use with caution with EFV and LPV/r: may need dose adjustment because of 
increased sedation, confusion and respiratory depression
Clonazepam • EFV: possible increase or decrease in clonazepam levels; avoid combination
• NVP: possible decrease in clonazepam concentrations and symptoms of 
withdrawal
• RTV: likely to increase levels of clonazepam – use with caution
Alprazolam • EFV: may increase levels of alprazolam – avoid
• RTV: increases alprazolam effect when RTV is started; after 10 days no 
significant interaction
• NVP: may reduce alprazolam effect
Midazolam • Do not co-administer with EFV, indinavir or LPV/r
• Use with caution with NVP
Lorazepam/oxazepam • No clinically significant interaction expected
IV = intravenous; IM  = intramuscular; EFV = efavirenz; RTV = ritonavir; LPV/r = lopinavir/ritonavir; NVP = nevirapine. 
Table 5. Approach to prescribing psychotropics for the agitated patient
Step Agent Dose Notes




Lorazepam 1 - 2 mg (maximum 12 mg/day) Repeat after 45 min to a maximum of 12 mg/day
Promethazine 20 - 25 mg Daily
IM/IV (second step 
after oral measures 
have failed/are not 
possible)
Lorazepam 1 - 4 mg IM Have flumazenil to hand in case of respiratory 
depression
Haloperidol 5 mg IM Should be the last drug considered as incidence of 
acute dystonia is high
Diazepam 10 mg over 10 min IV (never IM) Repeat after 10 min if insufficient effect (up to 3 
times)
IVI = intraveous; IM = intramuscular.





Either fluoxetine (for patients on first-line 
ART regimens) or citalopram (for patients on 
second-line regimens or receiving PIs) could 
be commenced at half the usual starting dose. 
Citalopram needs to be psychiatrist-initiated, 
but has the advantage over fluoxetine of being 
a scored tablet, making it easier to start at 
half the usual dose (10 mg). Venlafaxine 
(psychiatrist-initiated) should be considered 
for patients who have not responded to SSRIs. 
Benzodiazepines (Table 4) provide rapid 
symptomatic relief of anxiety, but because of 
their potential to cause physical dependence and 
withdrawal symptoms,11 and the potential for 
abuse, these drugs should be used at the lowest 
effective dose for the shortest period of time 
(<3 weeks). Benzodiazepines should be used 
in conjunction with SSRIs during treatment 
initiation. Caution should be exercised because 
of serious interactions with ARVs, particularly 
ritonavir (RTV), and especially with alprazolam, 
midazolam and triazolam. Lorazepam and 
oxazepam have the least number of interactions 
with ARVs. Benzodiazepines also cause 
or exacerbate cognitive impairment and are 
sedating; therefore, patients must be advised 
not to drive, operate machinery or drink alcohol 
concurrently with their use. 
Psychosis
Psychosis can occur at any time during the 
course of HIV disease. A psychotic syndrome 
includes at least 2 of the following symptoms:
• delusions (fixed false beliefs)
• hallucinations (auditory and other)
• disorganised speech or thought 
• disorganised behaviour.
Psychotic disorders include schizophrenia, 
substance-induced psychosis, and psychosis 
secondary to a general medical condition such 
as HIV. Reported rates of new-onset psychosis in 
HIV-positive patients range from 0.5% to 15%.12 
It is essential to differentiate psychotic 
symptoms caused by delirium or 
encephalopathy, to identify and treat the 
underlying cause; although short-term 
symptomatic treatment may include low-dose 
antipsychotics. In delirium, the psychotic 
symptoms may occur in the context of 
fluctuating attention, sleep/wake disturbance 
and poor orientation.
Anti-psychotics
Importantly, with regard to prescribing 
antipsychotics, HIV-positive patients may 
be more susceptible to extra-pyramidal 
side-effects (EPSEs), neuroleptic malignant 
syndrome and tardive dyskinesia. 
Antipsychotics should always be initiated at 
the lowest effective dose and for the shortest 
period of time necessary. Atypical or second-
generation antipsychotics (SGAs), where 
available, are  generally preferred over first-
generation antipsychotics, because of the 
decreased risk of EPSEs. Risperidone is the 
most widely studied atypical antipsychotic 
(or SGA), and generally appears to be safe, 
although levels have been reported to increase 
with concurrent RTV use.2,13 An overlap in 
metabolic side-effect profiles, e.g. weight gain, 
dyslipidaemia and impaired glucose tolerance 
of the SGAs and ARVs (PIs and nucleoside 
reverse transcriptase inhibitors (NRTIs) in 
particular), complicates the risk-to-benefit 
equation.14,15
Beside the interactions between 
risperidone and RTV, antipsychotics do 
not generally significantly inhibit or induce 
P-450 enzymes and can safely be added to 
HAART regimens without causing toxicity 
or HAART failure. Theoretically, RTV may 
increase the serum levels of haloperidol; 
therefore, close monitoring of adverse effects 
is advised.
The use of clozapine in HIV-positive patients 
is not routinely recommended, although it 
may be helpful in otherwise medically stable 
patients with higher CD4 cell counts.2 It is not 
Fig. 1. Decision tree for initiating appropriate anti-psychotic treatment for psychosis in HIV-infected 
individuals. EPSE = extra-pyramidal side-effects; WCC = white cell count; LFTs = liver function tests.
*Risperidone and quetiapine may be initiated ONLY by a psychiatrist.
†Depot medications are not contra-indicated. Consider a zuclopenthixol depot if clinically indicated; use 
a test dose of 50 - 100 mg, and repeat in 1 week. Thereafter, the depot can be administered monthly.





known whether HIV-positive patients receiving 
clozapine have a greater risk of agranulocytosis; 
therefore, extremely close monitoring of white 
cell count is recommended. Clozapine should 
only be initiated by a psychiatrist. The drug 
should be used with caution with LPV and 
RTV,8,9 as this could increase clozapine plasma 
concentrations, resulting in an increased risk 
of arrhythmias, seizures and haematological 
effects.
A guide to initiating appropriate treatment is 
provided in Fig. 1. Benzodiazepines can be added 
in the initial stages for agitation or aggressive 
or disruptive behaviour. Following diagnosis, a 
depot preparation can be given if adherence is 
likely to be a problem (or if the patient chooses 
it). A test dose should be considered.
Agitation
Aggressive or disruptive behaviour can occur 
in the context of psychiatric illness, physical 
illness, substance abuse or personality disorder. 
This can put staff and patients at risk. In general, 
it is important to attempt to examine the patient 
as thoroughly as possible before sedation to 
establish the underlying aggravating factors. 
It is also crucial to gain help from nursing 
staff, doctors and security staff where possible. 
The safety of the clinician, other patients and 
staff must be ensured. Non-pharmacological 
methods should be attempted first, e.g. talking 
down, distracting, and reassuring the patient. 
The patient must not be threatened, as this often 
escalates the situation. Oral treatment must be 
offered first and biperiden must be available if 
neuroleptics are introduced. Drug interactions 
between benzodiazepines and ARVs, and the 
approach to prescribing psychotropics in the 
agitated patient are summarised in Tables 4 and 
5, respectively.
Sleep disturbance
A patient with insomnia may have difficulty 
with falling asleep, early-morning wakening 
and/or frequent waking during the night. 
Before treating insomnia with drugs (Table 6), it 
is important to consider and address underlying 
reversible causes such as depression, mania, 
pain, medication side-effects, substance abuse, 
and poor sleep hygiene. It must be ascertained 
whether the patient has realistic expectations of 
sleep and whether other medications are being 
given at appropriate times, e.g. stimulating 
drugs in the morning and sedating drugs at 
night. If medication is prescribed, then the 
lowest effective dose for short-term use only 
must be used, and patients must be advised of 
interactions with alcohol.
Pain
Pain symptoms are common in HIV infection 
and may be caused by painful neuropathy, 
headaches, cancers and secondary infections. 
Pain disorders may be acute or chronic, with 
the latter often accompanied by depression, 
anxiety, and/or sleep disorders. In addition 
to analgesia use, psychotropics are frequently 
used to ameliorate pain symptoms:
• TCAs (e.g. amitriptyline at doses 25 - 
75 mg at night): refer to the section on 
‘Depression’ for further information. Other 
antidepressants should be considered if 
co-morbid depression is present. Duloxetine 
is an antidepressant registered for chronic 
pain but is not on State code in SA.
• Anti-convulsants: carbamazepine is 
not advised because of interactions with 
ARVs.8,9 Gabapentin (Lyrica) is used in 
chronic pain, but is not freely available.
Bipolar affective 
disorder/mania
The essential characteristic of a bipolar mood 
disorder is one or more manic (or hypomanic) 
episodes with/without depressive episodes. 
Mania is a recognised presentation in HIV-
infected individuals. A manic episode, which 
is severe enough to impair functioning or 
warrant hospitalisation, is characterised by 
abnormal and persistently elevated, expansive 
or irritable mood, with: grandiosity; decreased 
need for sleep; talkativeness; flight of ideas/
accelerated thoughts; distractibility; and/or 
increased involvement in pleasurable activities 
with potentially negative consequences, e.g. 
excessive buying or sexual indiscretions.
Mood stabilisation
Management is described in Fig. 2. HIV-positive 
individuals may be more sensitive to the side-
Table 6. Available classes of psychotropics for insomnia*
Agent Dose Side-effects
Promethazine 10 - 25 mg Can cause dry mouth and ‘hangover’ 
effect
Amitriptyline 10 - 25 mg Useful in patients with peripheral 
neuropathy
Oxazepam 15 - 30 mg Risk of dependency; prescribe no 
more than 14 days’ supply, unless 
prescribed by a psychiatrist or 
neurologist 
*Refer to the text for ARV drug interactions.
Fig. 2. An approach to the HIV-infected patient with mania. HAART = highly active antiretroviral therapy.





effects of mood-stabilisers, especially in the case 
of neurocognitive dysfunction. Agents such as 
valproate, lamotrigine and lithium may be used 
cautiously, but carbamazepine (Tegretol) should 
be avoided because of potential interactions 
with ARVs (RTV, NVP and EFV), and the risk 
of neutropenia.2,8,9 
Valproate (Epilim) is generally considered 
the first-line treatment, but there is an additive 
risk of fatty liver with didanosine (ddI), 
abacavir (ABC), lamivudine (3TC), stavudine 
(d4T) and zidovudine (AZT). It is important 
to monitor the patient’s liver function and 
adjust the dose accordingly, and it is advisable 
to test pre-treatment hepatic transaminases 
(AST/ALT) and platelet levels. The potential 
for teratogenesis in women of child-bearing 
age remains a concern. Some drug interactions 
do occur with LPV/r and LPV. Valproate levels 
may be decreased with co-administratiokn of 
RTV. An increase in the dose of valproate may 
be requried. No significant interaction occurs 
with tenofovir (TDF), NVP or EFV.8,9
Lithium should be avoided in patients 
with dehydration and renal function 
impairment. The agent is not always well 
tolerated, and it may be advisable to limit 
its use to individuals with higher CD4 cell 
counts.2 Careful monitoring of lithium levels 
is needed, usually 5 days after any dose 
adjustment, then monthly and 3 - 6-monthly 
thereafter. 
Lamotrigine (Lamictin) can also 
be considered and is mainly used for 
depression in bipolar disorder. In most State 
facilities its use needs to be initiated by a 
psychiatrist or neurologist and the dose 
needs to be increased gradually to avoid 
Stevens-Johnson syndrome. RTV decreases 
lamotrigine levels by about 50% due to 
induction of glucuronidation; therefore, 
an increased lamotrigine dosage may be 
required.
Additional treatments that can be used 
in manic episodes include antipsychotics 
(such as Risperidone and Quetiapine) and 
benzodiazepines.
Conclusion
Many patients with HIV/AIDS have co-
occurring mental health conditions that affect 
ART adherence, quality of life, morbidity 
and mortality. Although close collaboration 
between physicians, psychiatrists and other 
members of the multidisciplinary healthcare 
team is the ideal, many clinicians work in 
settings where psychiatric support is not readily 
available. This article is intended to guide 
prescribing antipsychotics in these settings. 
Additional resources
• Medicines Information Centre: http://www.
mic.uct.ac.za; tel: +27 (0)21 406 6829 
• HIV drug interactions: http://www.hiv-
druginteractions.org
• Psychiatry services and resources in the 
Western Cape province: http://www.
hivmentalhealth.co.za.
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